This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Immunization  • Pneumonia  • Bacterial Infections  • Travel Medicine  • Alert me on articles by topic

Harunor Rashid, MBBS, DCH; Shuja Shafi, MBBS, FRCPath; Elizabeth Haworth, MBBS, FFPHM; Robert Booy, MBBS, MD

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In their recent article, Johnstone et al¹ demonstrated that for the years 2000 to 2002, hospitalized Canadian adults with community-acquired pneumonia who had previously received 23-valent polysaccharide pneumococcal vaccine (PPV) experienced lower mortality or less need for intensive care unit admission compared with unvaccinated patients. However, the investigators pointed out that only 215 of 2416 eligible patients (9%) were vaccinated at hospital discharge.¹ A recent UK-based study showed that depending on the risk, vaccine uptake in at-risk individuals ranged from 13% to 69% but was substantially lower in populations where the proportion of nonwhites exceeds 10%.² Marked ethnic disparities were also reported among American elderly adults.³The uptake of PPV among Muslims attending the Hajj pilgrimage in Mecca, Saudi Arabia, is not known, even though up to 12% of the lower respiratory tract infections . . . [Full Text of this Article]

AUTHOR INFORMATION

RELATED ARTICLE

Effect of Pneumococcal Vaccination in Hospitalized Adults With Community-Acquired Pneumonia
Jennie Johnstone, Thomas J. Marrie, Dean T. Eurich, and Sumit R. Majumdar
Arch Intern Med. 2007;167(18):1938-1943.
ABSTRACT | FULL TEXT